• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

AbbVie to Buy Pharmacyclics for $21 Billion

Article

March 5, 2015.

AbbVie Inc. (North Chicago, IL) is to buy Pharmacyclics (Sunnyvale, CA) for "about $21 billion", Reuters reports today.

The deal will give AbbVie access to what is expected to be one of the world's top-selling cancer drugs: Pharmacyclics' blood cancer treatment Imbruvica is predicted to hit $1 billion in US sales this year, with worldwide sales to reach $5.8 billion by 2020, according to Thomson Reuters Cortellis.

 

 

Recent Videos
Related Content